Abstract
Summary
A 4 × 4 Latin square design was used in determining the effect of daily oral doses of 0, 0.5, 1.0 or 2.0 mg/kg of 6α,7α-difluoromethylene-4′,5′-dihydro-1α,2α-methylene- (17R) - spiro- [androst-4-ene-17,2′ (3′H)-furan]-3-one (Compound I), on the volume, acid phosphatase concentration and total acid phosphatase of prostatic fluid collected from four cystopreputiostomized beagles.
After the 6 day treatment period, dogs given 0.5 mg/kg showed a significant reduction in concentration of prostatic acid phosphatase. The 1.0 mg/kg level caused significant decreases in both concentration and total amount of acid phosphatase. In dogs which received the 2.0 mg/kg dose, all three parameters measured were significantly reduced by treatment.
The results of this experiment are believed to reflect the anti-androgenic activity of Compound I.
Get full access to this article
View all access options for this article.